{'fraction_non_alphanumeric': 0.02711323763955343, 'fraction_numerical': 0.022328548644338118, 'mean_word_length': 5.343434343434343, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Mitoxantrone—A Useful Palliative Therapy in Advanced Breast Cancer

We have treated 76 patients with advanced breast cancer with single-agent mitoxantrone: all had previously received hormone therapy and 30 patients had also received prior chemotherapy. The overall response rate at 6 months was 15%, with a further 22% having static disease. Responding and static patients had similar survival curves and were grouped together as patients with “stable disease.” Patients with stable disease had a significantly longer survival than patients with progressive disease (p < 0.001): the median difference in survival was 9 months.